Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T therapy could ...

Gilead/Kite have aspirations to challenge Kymriah in paediatric ALL as well, and are currently running the phase 1/2 ZUMA-4 trial in children and adolescents with this type of blood cancer.

Lobo, who is also an orthopaedic doctor, competed in kite surfing at the 2024 Paris Olympics. He is also a two-time Pan American Games champion. At the time of the rescue, he was busy training ...

In trading on Thursday, shares of NewAmsterdam Pharma Company N V (Symbol: NAMS) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $19.60 per share.

NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...

NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on NewAmsterdam Pharma (NASDAQ:NAMS) in the last three months. The following table summarizes ...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a biopharmaceutical company with a market capitalization of $2.3 billion ...